MA37438A1 - Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora - Google Patents
Procédés de traitement du cancer utilisant des inhibiteurs de la kinase auroraInfo
- Publication number
- MA37438A1 MA37438A1 MA37438A MA37438A MA37438A1 MA 37438 A1 MA37438 A1 MA 37438A1 MA 37438 A MA37438 A MA 37438A MA 37438 A MA37438 A MA 37438A MA 37438 A1 MA37438 A1 MA 37438A1
- Authority
- MA
- Morocco
- Prior art keywords
- kinase inhibitors
- cancer treatment
- treatment methods
- aurora kinase
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des procédés pour le traitement de divers troubles prolifératifs cellulaires. L'invention concerne en particulier des procédés pour le traitement de divers troubles prolifératifs cellulaires par administration d'un inhibiteur sélectif de la kinase aurora a en combinaison avec une chimiothérapie à base de taxane, tel que le paclitaxel ou le docétaxel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261613258P | 2012-03-20 | 2012-03-20 | |
PCT/US2013/032962 WO2013142491A1 (fr) | 2012-03-20 | 2013-03-19 | Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora |
Publications (1)
Publication Number | Publication Date |
---|---|
MA37438A1 true MA37438A1 (fr) | 2016-05-31 |
Family
ID=48048255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37438A MA37438A1 (fr) | 2012-03-20 | 2013-03-19 | Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora |
Country Status (25)
Country | Link |
---|---|
US (2) | US20130303519A1 (fr) |
EP (1) | EP2827855B1 (fr) |
JP (1) | JP6373252B2 (fr) |
KR (1) | KR102128866B1 (fr) |
CN (1) | CN104271129A (fr) |
AU (1) | AU2013235275B2 (fr) |
CA (1) | CA2868024A1 (fr) |
EA (1) | EA036434B1 (fr) |
ES (1) | ES2746946T3 (fr) |
GE (1) | GEP20186900B (fr) |
HK (1) | HK1206253A1 (fr) |
IL (1) | IL234686B (fr) |
IN (1) | IN2014DN08477A (fr) |
JO (1) | JO3630B1 (fr) |
MA (1) | MA37438A1 (fr) |
MX (1) | MX358411B (fr) |
MY (1) | MY175225A (fr) |
NZ (1) | NZ700744A (fr) |
PH (1) | PH12014502109A1 (fr) |
SG (2) | SG10201607741RA (fr) |
TN (1) | TN2014000387A1 (fr) |
TW (1) | TWI649082B (fr) |
UA (1) | UA117455C2 (fr) |
WO (1) | WO2013142491A1 (fr) |
ZA (1) | ZA201407551B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
CA2972076A1 (fr) * | 2014-12-23 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | Combinaison d'inhibiteurs de raf et d'inhibiteurs de kinases aurora |
JP6786530B2 (ja) * | 2015-07-02 | 2020-11-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | オーロラaキナーゼの選択的インヒビターに対する応答のバイオマーカー |
CN110833544B (zh) * | 2018-08-17 | 2022-08-09 | 深圳微芯生物科技股份有限公司 | 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
NL8000715A (nl) | 1979-02-07 | 1980-08-11 | Hoffmann La Roche | Pyrimido-2-benzazepinen, werkwijzen ter bereiding ervan, alsmede farmaceutische preparaten, die deze pyrimido-2- benzazepinen bevatten. |
US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
EP0273697A3 (fr) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-Benzazépines à cycles hétérocycliques de 5 et 6 côtés |
US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5747487A (en) | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
KR19990087585A (ko) | 1996-03-08 | 1999-12-27 | 돈 리사 로얄 | 신경학적 활성제로서의 아졸로벤즈아제핀 유도체 |
WO1998028281A1 (fr) | 1996-12-23 | 1998-07-02 | Celltech Therapeutics Limited | Derives polycyclique fondus de 2-aminopyrimidine, leur preparation et leur utilisation comme inhibiteurs de proteine tyrosine-kinase |
GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
DK1026167T3 (da) | 1997-09-29 | 2003-05-26 | Meiji Seika Kaisha | Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler |
US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
WO2000067754A1 (fr) | 1999-05-12 | 2000-11-16 | Nitromed, Inc. | Activateurs nitroses et nitrosyles du canal potassique, compositions et utilisations |
EP1317448B2 (fr) | 2000-09-15 | 2011-05-04 | Vertex Pharmaceuticals Incorporated | Composes a base de pyrazole pouvant etre utilises comme inhibiteurs de la proteine kinase |
DE60120219T2 (de) | 2000-12-21 | 2007-04-12 | Vertex Pharmaceuticals Inc., Cambridge | Pyrazolverbindungen als protein-kinase-inhibitoren |
SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
DE10135457A1 (de) | 2001-07-20 | 2003-02-06 | Adc Automotive Dist Control | Optische Sensoranordnung |
IL159963A0 (en) | 2001-08-09 | 2004-06-20 | Actelion Pharmaceuticals Ltd | Novel benzo-fused heterocycles as endothelin antagonisits |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
CA2554271A1 (fr) | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combinaison d'un inhibiteur de la pompe a protons, d'un tampon et d'un medicament anti-inflammatoire non steroidien |
RS52436B (en) | 2004-05-14 | 2013-02-28 | Millennium Pharmaceuticals Inc. | UNITS AND PROCEDURES FOR THE INHIBITION OF MITOSIS PROGRESS BY INHIBITION OF AUROR KINASE |
JP2008520713A (ja) | 2004-11-17 | 2008-06-19 | ミイカナ セラピューティクス インコーポレイテッド | キナーゼ阻害剤 |
JP2008526723A (ja) | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Cdk、gsk及びオーロラキナーゼの活性を調節するピラゾール誘導体 |
SI1962830T1 (sl) | 2005-12-23 | 2013-07-31 | Glaxosmithkline Llc | Azaindolni inhibitorji kinaz Aurora |
WO2007080601A1 (fr) | 2006-01-16 | 2007-07-19 | Jubilant Organosys Limited | Formulation pharmaceutique stable d'un compose labile a base d'acide et son procede de preparation |
US20070238716A1 (en) | 2006-03-14 | 2007-10-11 | Murthy Ayanampudi S R | Statin stabilizing dosage formulations |
DE102006012301A1 (de) | 2006-03-15 | 2007-09-20 | Cemag-Anlagenbau-Dessau Gmbh | Herstellung von Zementklinker |
EP2054413A2 (fr) | 2006-08-09 | 2009-05-06 | Millennium Pharmaceuticals, Inc. | Pyridobenzazépines et méthodes d'inhibition de la progression mitotique |
CN101528237A (zh) | 2006-10-31 | 2009-09-09 | 艾其林医药公司 | 艾夫他滨药物组合物 |
CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
AR065802A1 (es) | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
US20110033461A1 (en) * | 2008-03-12 | 2011-02-10 | Vladimir Ratushny | Combination Therapy for the Treatment of Cancer |
WO2009158687A1 (fr) | 2008-06-26 | 2009-12-30 | Anterios, Inc. | Administration dermique |
JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
BR112012020557A8 (pt) * | 2010-02-19 | 2018-01-02 | Millennium Pharm Inc | formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio |
US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
-
2013
- 2013-03-14 US US13/804,570 patent/US20130303519A1/en not_active Abandoned
- 2013-03-18 JO JOP/2013/0075A patent/JO3630B1/ar active
- 2013-03-19 NZ NZ700744A patent/NZ700744A/en not_active IP Right Cessation
- 2013-03-19 JP JP2015501852A patent/JP6373252B2/ja active Active
- 2013-03-19 KR KR1020147028776A patent/KR102128866B1/ko active IP Right Grant
- 2013-03-19 SG SG10201607741RA patent/SG10201607741RA/en unknown
- 2013-03-19 AU AU2013235275A patent/AU2013235275B2/en active Active
- 2013-03-19 MA MA37438A patent/MA37438A1/fr unknown
- 2013-03-19 WO PCT/US2013/032962 patent/WO2013142491A1/fr active Application Filing
- 2013-03-19 SG SG11201405621UA patent/SG11201405621UA/en unknown
- 2013-03-19 UA UAA201411324A patent/UA117455C2/uk unknown
- 2013-03-19 CN CN201380015806.1A patent/CN104271129A/zh active Pending
- 2013-03-19 IN IN8477DEN2014 patent/IN2014DN08477A/en unknown
- 2013-03-19 ES ES13714455T patent/ES2746946T3/es active Active
- 2013-03-19 CA CA2868024A patent/CA2868024A1/fr not_active Abandoned
- 2013-03-19 EA EA201491727A patent/EA036434B1/ru not_active IP Right Cessation
- 2013-03-19 EP EP13714455.6A patent/EP2827855B1/fr active Active
- 2013-03-19 MY MYPI2014702635A patent/MY175225A/en unknown
- 2013-03-19 GE GEAP201313599A patent/GEP20186900B/en unknown
- 2013-03-19 MX MX2014011324A patent/MX358411B/es active IP Right Grant
- 2013-03-20 TW TW102109912A patent/TWI649082B/zh active
-
2014
- 2014-09-15 TN TNP2014000387A patent/TN2014000387A1/fr unknown
- 2014-09-16 IL IL234686A patent/IL234686B/en active IP Right Grant
- 2014-09-22 PH PH12014502109A patent/PH12014502109A1/en unknown
- 2014-10-17 ZA ZA2014/07551A patent/ZA201407551B/en unknown
-
2015
- 2015-07-17 HK HK15106841.1A patent/HK1206253A1/xx unknown
- 2015-09-03 US US14/844,270 patent/US10213436B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016502066A1 (en) | Methods of treating bladder cancer | |
MX2018004832A (es) | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. | |
GEP20217211B (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
MA38959A1 (fr) | Modulateurs du facteur b du complément | |
MX2021007651A (es) | Inhibidores de ezh2 para tratar linfomas. | |
MX2015011753A (es) | Metodos para tratar cancer de vegija. | |
MX351148B (es) | Formulacion de anticuerpo beta amiloide. | |
CL2013003160A1 (es) | Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros. | |
CL2011000043A1 (es) | Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central. | |
GB201204263D0 (en) | Giloma treatment | |
PA8851101A1 (es) | Compuesto amino pirazol | |
ECSP12011658A (es) | Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia | |
EA201491647A1 (ru) | Основанные на арилэфирах ингибиторы киназ | |
MX2012013495A (es) | Ligandos sigma para la revolucion y/o el tratamiento de la emesis inducida por quimioterapia o radioterapia. | |
MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
MA37438A1 (fr) | Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora | |
MA34952B1 (fr) | Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme | |
EA201500368A1 (ru) | Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии | |
EA201692531A1 (ru) | Способы лечения инфекций | |
NZ711046A (en) | Nanoparticles containing a taxane and their use | |
CL2015000874A1 (es) | Pde9i con estructura principal de imidazopirazinona | |
MA43609B1 (fr) | Compositions et méthodes de traitement de l'anémie |